DKDominic F. Kelly

Dominic F. Kelly

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Dominic F. Kelly has a total of 119 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Vitamin D may influence disease course in PIMS ‐ TS / MIS ‐C: An observational cohort study

    by James E. G. Charlesworth, Joshua Navarajasegaran, Akhila Kavirayani, Avishay Sarfatti, Satish Adwani, Stéphane Paulus, Shelley Segal, James J. Gilchrist, Dominic F. Kelly, Emily A. Lees

    Background: Pediatric multisystem inflammatory syndrome temporally associated with SARS‐CoV‐2 (PIMS‐TS) remains an enigmatic disease process, with phenotypic similarities to Kawasaki disease, although many patients present with transient cardiac dysfunction. Biomarkers help validate diagnosis, but the correlation of biomarkers to disease severity or prognosis is poorly understood. Design: We retrospectively reviewed PIMS‐TS patients treated in Oxford between May 2020 and May 2022. Data on demographics, presenting features, biochemical markers, treatment, and outcomes were reviewed, and patients with/without the need for vasoactive medications were compared. Results: We identified 63 patients, median age 10.3 years (range 1.2–15.2 years). Where tested, 51/54 (94.4%) were SARS‐CoV‐2‐antibody positive. Admissions followed regional peaks in SARS‐CoV‐2 infection. Forty children (63.5%) required vasoactive medications. Amongst those requiring vasoactive medications, peak NT‐pro‐BNP (median 11,363 ng/L vs. 3741 ng/L, p = 0.004) and length of stay (median 8.4 vs. 6.4 days, p = 0.021) were greater. Vitamin D levels inversely correlated with peak CRP (spearman r = −0.34, p = 0.007) and duration of vasoactive medications (spearman r = −0.34, p = 0.030). Furthermore, low serum vitamin D correlated with lower SARS‐CoV‐2 anti‐nucleocapsid titers (spearman r = 0.43, p = 0.0014). Children receiving IV methylprednisolone, 54/63 (85.7%) (of whom, 16/54 received IVIg and methylprednisolone) had a more rapid fall in CRP than those given IVIg alone (7/63; 11.1%) or no immunomodulatory treatment (2/63; 3.2%). No patients had coronary artery aneurysm or persistent cardiac sequelae at discharge. Conclusions: Methylprednisolone suppressed CRP early and without evidence of coronary aneurysm in this cohort. We demonstrate a relationship between vitamin D, SARS‐CoV‐2 anti‐nucleocapsid antibody production, inflammatory biomarkers, and duration of vasoactive medication, requiring further validation.


  • Open Access

    Computational mining of B cell receptor repertoires reveals antigen-specific and convergent responses to Ebola vaccination

    by Eve Richardson, Sagida Bibi, Florence McLean, Lisa Schimanski, Pramila Rijal, Marie Ghraichy, Valentin von Niederhäusern, Johannes Trück, Elizabeth A. Clutterbuck, Daniel O’cOnnor, et al.

    Outbreaks of Ebolaviruses, such as Sudanvirus (SUDV) in Uganda in 2022, demonstrate that species other than the Zaire ebolavirus (EBOV), which is currently the sole virus represented in current licensed vaccines, remain a major threat to global health. There is a pressing need to develop effective pan-species vaccines and novel monoclonal antibody-based therapeutics for Ebolavirus disease. In response to recent outbreaks, the two dose, heterologous Ad26.ZEBOV/MVA-BN-Filo vaccine regimen was developed and was tested in a large phase II clinical trial (EBL2001) as part of the EBOVAC2 consortium. Here, we perform bulk sequencing of the variable heavy chain (VH) of B cell receptors (BCR) in forty participants from the EBL2001 trial in order to characterize the BCR repertoire in response to vaccination with Ad26.ZEBOV/MVA-BN-Filo. We develop a comprehensive database, EBOV-AbDab, of publicly available Ebolavirus-specific antibody sequences. We then use our database to predict the antigen-specific component of the vaccinee repertoires. Our results show striking convergence in VH germline gene usage across participants following the MVA-BN-Filo dose, and provide further evidence of the role of IGHV3–15 and IGHV3–13 antibodies in the B cell response to Ebolavirus glycoprotein. Furthermore, we found that previously described Ebola-specific mAb sequences present in EBOV-AbDab were sufficient to describe at least one of the ten most expanded BCR clonotypes in more than two thirds of our cohort of vaccinees following the boost, providing proof of principle for the utility of computational mining of immune repertoires.


  • Open Access

    Evaluation of Acute and Convalescent Antibody Concentration Against Pneumococcal Capsular Polysaccharides for the Diagnosis of Pneumococcal Infection in Children with Community-Acquired Pneumonia

    by Michael J. Carter, Sonu Shrestha, Peter O’rEilly, Pallavi Gurung, Meeru Gurung, Stephen Thorson, Rama Kandasamy, Merryn Voysey, Elizabeth O’mAhony, Sarah Kelly, et al.

    We evaluated whether the quantification of IgG to pneumococcal capsular polysaccharides is an accurate diagnostic test for pneumococcal infection in children with pneumonia in Nepal. Children with pneumococcal pneumonia did not have higher convalescent, or higher fold change, IgG to pneumococcal polysaccharides than children with other causes of pneumonia. Caution is needed in interpreting antibody responses in pneumococcal infections.


  • Open Access

    Intracranial Empyema in Children: A Single-center Retrospective Case Series

    by James J. Gilchrist, Tom Mbbs Hoy, Else M. Bijker, Emily A. Lees, Laura MChem Wilkins, Madeleine Ba Oliver, Dominic F. Kelly, Stéphane C. Paulus, Amedeo PhD Calisto

    We conducted a retrospective, observational study of 42 children with intracranial empyema admitted to a pediatric neurosurgical center over a 9-year period. Intracranial empyema is rare, but causes significant morbidity and mortality. Twenty-eight cases had neurosurgical source control, more commonly for subdural collections. Streptococcus anginosus group bacteria are important pathogens in subdural empyema, whose isolation predicts more complicated postoperative courses.


  • Open Access

    Molecular correlates of vaccine-induced protection against typhoid fever

    by Henderson Zhu, Irina Chelysheva, Deborah L. Cross, Luke Blackwell, Celina Jin, Malick M. Gibani, Elizabeth Jones, Jennifer Hill, Johannes Trück, Dominic F. Kelly, et al.

    BACKGROUND. Typhoid fever is caused by the Gram-negative bacterium Salmonella enterica serovar Typhi and poses a substantial public health burden worldwide. Vaccines have been developed based on the surface Vi-capsular polysaccharide of S. Typhi; these include a plain-polysaccharide-based vaccine, ViPS, and a glycoconjugate vaccine, ViTT. To understand immune responses to these vaccines and their vaccine-induced immunological protection, molecular signatures were analyzed using bioinformatic approaches. METHODS. Bulk RNA-Seq data were generated from blood samples obtained from adult human volunteers enrolled in a vaccine trial, who were then challenged with S. Typhi in a controlled human infection model (CHIM). These data were used to conduct differential gene expression analyses, gene set and modular analyses, B cell repertoire analyses, and time-course analyses at various post-vaccination and post-challenge time points between participants receiving ViTT, ViPS, or a control meningococcal vaccine. RESULTS. Transcriptomic responses revealed strong differential molecular signatures between the 2 typhoid vaccines, mostly driven by the upregulation in humoral immune signatures, including selective usage of immunoglobulin heavy chain variable region (IGHV) genes and more polarized clonal expansions. We describe several molecular correlates of protection against S. Typhi infection, including clusters of B cell receptor (BCR) clonotypes associated with protection, with known binders of Vi-polysaccharide among these. CONCLUSION. The study reports a series of contemporary analyses that reveal the transcriptomic signatures after vaccination and infectious challenge, while identifying molecular correlates of protection that may inform future vaccine design and assessment. TRIAL REGISTRATION. ClinicalTrials.gov NCT02324751.


  • Open Access

    14-year trends and resistance patterns of blood and cerebrospinal fluid cultures in children under three years old

    by Junko Takata, Dominic F Kelly, Manish Sadarangani, Katie Jeffery, Simon B Drysdale


  • Open Access

    A computational method for immune repertoire mining that identifies novel binders from different clonotypes, demonstrated by identifying anti-Pertussis toxoid antibodies

    by Eve Richardson, Jacob D. Galson, Paul Kellam, Dominic F. Kelly, Sarah E. Smith, Anne Palser, Simon Watson, Charlotte M. Deane

    Due to their shared genetic history, antibodies from the same clonotype often bind to the same epitope. This knowledge is used in immune repertoire mining, where known binders are used to search bulk sequencing repertoires to identify new binders. However current computational methods cannot identify epitope convergence between antibodies from different clonotypes, limiting the sequence diversity of antigen-specific antibodies which can be identified. We describe how the antibody binding site, the paratope, can be used to cluster antibodies with common antigen reactivity from different clonotypes. Our method, paratyping, uses the predicted paratope to identify these novel cross clonotype matches. We experimentally validated our predictions on a Pertussis toxoid dataset. Our results show that even the simplest abstraction of the antibody binding site, using only the length of the loops involved and predicted binding residues, is sufficient to group antigen-specific antibodies and provide additional information to conventional clonotype analysis.


  • Open Access

    Inferring B cell specificity for vaccines using a Bayesian mixture model

    by Anna Fowler, Jacob D. Galson, Johannes Trück, Dominic F. Kelly, Gerton Lunter

    Background: Vaccines have greatly reduced the burden of infectious disease, ranking in their impact on global health second only after clean water. Most vaccines confer protection by the production of antibodies with binding affinity for the antigen, which is the main effector function of B cells. This results in short term changes in the B cell receptor (BCR) repertoire when an immune response is launched, and long term changes when immunity is conferred. Analysis of antibodies in serum is usually used to evaluate vaccine response, however this is limited and therefore the investigation of the BCR repertoire provides far more detail for the analysis of vaccine response.Results: Here, we introduce a novel Bayesian model to describe the observed distribution of BCR sequences and the pattern of sharing across time and between individuals, with the goal to identify vaccine-specific BCRs. We use data from two studies to assess the model and estimate that we can identify vaccine-specific BCRs with 69% sensitivity.Conclusion: Our results demonstrate that statistical modelling can capture patterns associated with vaccine response and identify vaccine specific B cells in a range of different data sets. Additionally, the B cells we identify as vaccine specific show greater levels of sequence similarity than expected, suggesting that there are additional signals of vaccine response, not currently considered, which could improve the identification of vaccine specific B cells.


  • Open Access

    Maturation of the human B-cell receptor repertoire with age

    by Marie Ghraichy, Jacob D. Galson, Aleksandr Kovaltsuk, Valentin von Niederhaeusern, Jana Pachlopnik Schmid, Mike Recher, Annaïse J Jauch, Enkelejda Miho, Dominic F. Kelly, Charlotte M. Deane, et al.

    B cells play a central role in adaptive immune processes, mainly through the production of antibodies. The maturation of the B-cell system with age is poorly studied. We extensively investigated age-related alterations of naïve and antigen-experienced B-cell receptor (BCR) repertoires. The most significant changes were observed in the first 10 years of life, and were characterized by altered immunoglobulin gene usage and an increased frequency of mutated antibodies structurally diverging from their germline precursors. Older age was associated with an increased usage of downstream constant region genes and fewer antibodies with self-reactive properties. As mutations accumulated with age, the frequency of germline-encoded self-reactive antibodies decreased, indicating a possible beneficial role of self-reactive B-cells in the developing immune system. Our results suggest a continuous process of change through childhood across a broad range of parameters characterizing BCR repertoires and stress the importance of using well-selected, age-appropriate controls in BCR studies.


  • Open Access

    Inferring B cell specificity for vaccines using a mixture model

    by Anna Fowler, Jacob D. Galson, Johannes Trück, Dominic F. Kelly, Gerton Lunter

    Vaccines have greatly reduced the burden of infectious disease, ranking in their impact on global health second only after clean water. Most vaccines confer protection by the production of antibodies with binding affinity for the antigen, which is the main effector function of B cells. This results in short term changes in the B Cell receptor (BCR) repertoire when an immune response is launched, and long term changes when immunity is conferred. Analysis of antibodies in the serum is usually used to evaluate vaccine response, however this is limited and therefore the investigation of the BCR repertoire provides far more detail for the analysis of vaccine response. Here, we introduce a novel Bayesian model to describe the observed distribution of BCR sequences and the pattern of sharing across time and between individuals, with the goal to identify vaccine-specific BCR sequences. We use data from two studies to assess the model and estimate that we can identify vaccine-specific sequences with 69% sensitivity.